{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:43Z","timestamp":1792122223883,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-025-01371-z","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T05:37:00Z","timestamp":1779514620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research"],"prefix":"10.1007","volume":"27","author":[{"given":"Iraj","family":"Alipourfard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Shafaghat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saber","family":"Saharkhiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh Ramezani","family":"Farani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salar","family":"Bakhtiyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"5","key":"1371_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"26","key":"1371_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"7","key":"1371_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640\u201354.","journal-title":"N Engl J Med"},{"issue":"25","key":"1371_CR4","first-page":"3322","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood J Am Soc Hematol. 2017;129(25):3322\u201331.","journal-title":"Blood J Am Soc Hematol"},{"issue":"18","key":"1371_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"8","key":"1371_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrd.2018.93","volume":"17","author":"KD Warner","year":"2018","unstructured":"Warner KD, Hajdin CE, Weeks KM. Principles for targeting RNA with drug-like small molecules. Nat Rev Drug Discov. 2018;17(8):547\u201358.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1371_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371.","journal-title":"Nat Med"},{"issue":"1","key":"1371_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti G, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107\u201326.","journal-title":"Immunol Rev"},{"issue":"1","key":"1371_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","volume":"6","author":"M Mamonkin","year":"2018","unstructured":"Mamonkin M, et al. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol Res. 2018;6(1):47\u201358.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1371_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","journal-title":"Nat Med"},{"key":"1371_CR11","doi-asserted-by":"crossref","unstructured":"Huang Y et al. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies. Drug Resist Updates, 2024; 101082.","DOI":"10.1016\/j.drup.2024.101082"},{"issue":"1","key":"1371_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12967-024-04982-6","volume":"22","author":"J Ye","year":"2024","unstructured":"Ye J, et al. Combined therapy of CAR-IL-15\/IL-15R\u03b1-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer. J Translational Med. 2024;22(1):171.","journal-title":"J Translational Med"},{"issue":"1","key":"1371_CR13","doi-asserted-by":"publisher","first-page":"kyae019","DOI":"10.1093\/discim\/kyae019","volume":"4","author":"GR Smith","year":"2025","unstructured":"Smith GR, et al. The current landscape of optogenetics for the enhancement of adoptive T-cell therapy. Discovery Immunol. 2025;4(1):kyae019.","journal-title":"Discovery Immunol"},{"issue":"22","key":"1371_CR14","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1182\/bloodadvances.2020003391","volume":"4","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Maus MV. C (h) AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. Blood Adv. 2020;4(22):5858\u201362.","journal-title":"Blood Adv"},{"issue":"11","key":"1371_CR15","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1080\/10428194.2021.1913146","volume":"62","author":"A Gupta","year":"2021","unstructured":"Gupta A, Gill S. CAR-T cell persistence in the treatment of leukemia and lymphoma. Leuk Lymphoma. 2021;62(11):2587\u201399.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1371_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 2017;21(1):17\u201326.","journal-title":"Cell Rep"},{"issue":"10","key":"1371_CR17","doi-asserted-by":"publisher","first-page":"e009499","DOI":"10.1136\/jitc-2024-009499","volume":"12","author":"SK Silbert","year":"2024","unstructured":"Silbert SK, et al. CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy. J Immunother Cancer. 2024;12(10):e009499.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1371_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, et al. Off-the-shelf\u2019allogeneic CAR T cells: development and challenges. Nat Rev Drug Discovery. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discovery"},{"key":"1371_CR19","unstructured":"Li Y-R et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol, 2024:1\u201316."},{"issue":"4","key":"1371_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"key":"1371_CR21","unstructured":"Brentjens RJ et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science translational medicine, 2013. 5(177):177ra38-177ra38."},{"issue":"1","key":"1371_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bjh.14475","volume":"177","author":"RJ Orlowski","year":"2017","unstructured":"Orlowski RJ, Porter DL, Frey NV. The promise of chimeric antigen receptor T cells (CAR-Ts) in leukaemia. Br J Haematol. 2017;177(1):13\u201326.","journal-title":"Br J Haematol"},{"issue":"14","key":"1371_CR23","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41(14):2594\u2013606.","journal-title":"J Clin Oncol"},{"key":"1371_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","volume":"134","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134:6.","journal-title":"Blood"},{"issue":"9967","key":"1371_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328.","journal-title":"Lancet"},{"issue":"8","key":"1371_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"10297","key":"1371_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"10167","key":"1371_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EE Cohen","year":"2019","unstructured":"Cohen EE, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156\u201367.","journal-title":"Lancet"},{"key":"1371_CR29","doi-asserted-by":"crossref","unstructured":"Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag, 2019: 323\u201335.","DOI":"10.2147\/TCRM.S150524"},{"issue":"26","key":"1371_CR30","first-page":"3321","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood J Am Soc Hematol. 2016;127(26):3321\u201330.","journal-title":"Blood J Am Soc Hematol"},{"key":"1371_CR31","unstructured":"Davila ML et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014. 6(224):224ra25-224ra25."},{"issue":"9","key":"1371_CR32","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/jama.2020.1012","volume":"323","author":"I Hernandez","year":"2020","unstructured":"Hernandez I, et al. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007\u20132018. JAMA. 2020;323(9):854\u201362.","journal-title":"JAMA"},{"issue":"495","key":"1371_CR33","doi-asserted-by":"publisher","first-page":"eaaw2293","DOI":"10.1126\/scitranslmed.aaw2293","volume":"11","author":"S Mardiana","year":"2019","unstructured":"Mardiana S, et al. Supercharging adoptive T cell therapy to overcome solid tumor\u2013induced immunosuppression. Sci Transl Med. 2019;11(495):eaaw2293.","journal-title":"Sci Transl Med"},{"issue":"8","key":"1371_CR34","first-page":"983","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, et al. A T-cell\u2013directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood J Am Soc Hematol. 2015;126(8):983\u201392.","journal-title":"Blood J Am Soc Hematol"},{"issue":"S3","key":"1371_CR35","doi-asserted-by":"publisher","first-page":"e3515785","DOI":"10.1097\/01.HS9.0000967376.35157.85","volume":"7","author":"J Pan","year":"2023","unstructured":"Pan J, et al. S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. Hemasphere. 2023;7(S3):e3515785.","journal-title":"Hemasphere"},{"issue":"1","key":"1371_CR36","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi M, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun. 2024;15(1):3371.","journal-title":"Nat Commun"},{"issue":"2","key":"1371_CR37","doi-asserted-by":"publisher","first-page":"e3256","DOI":"10.1002\/hon.3256","volume":"42","author":"LY Wang","year":"2024","unstructured":"Wang LY, et al. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single\u2010center retrospective analysis. Hematol Oncol. 2024;42(2):e3256.","journal-title":"Hematol Oncol"},{"issue":"2","key":"1371_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332.","journal-title":"Nat Med"},{"issue":"8","key":"1371_CR39","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14712598.2022.2086043","volume":"22","author":"F Furqan","year":"2022","unstructured":"Furqan F, Shah NN. Bispecific CAR T-cells for B-cell malignancies. Expert Opin Biol Ther. 2022;22(8):1005\u201315.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"1371_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C de Fern\u00e1ndez","year":"2020","unstructured":"de Fern\u00e1ndez C, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma. Blood Cancer Discov. 2020;1(2):146\u201354.","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"1371_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390.","journal-title":"Nat Med"},{"issue":"14","key":"1371_CR42","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.3390\/cancers13143534","volume":"13","author":"AM Battram","year":"2021","unstructured":"Battram AM, et al. IL-15 enhances the persistence and function of BCMA-targeting CAR-T cells compared to IL-2 or IL-15\/IL-7 by limiting CAR-T cell dysfunction and differentiation. Cancers. 2021;13(14):3534.","journal-title":"Cancers"},{"issue":"16","key":"1371_CR43","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.3390\/ijms22168996","volume":"22","author":"T Haslauer","year":"2021","unstructured":"Haslauer T, et al. CAR T-cell therapy in hematological malignancies. Int J Mol Sci. 2021;22(16):8996.","journal-title":"Int J Mol Sci"},{"key":"1371_CR44","doi-asserted-by":"publisher","first-page":"102331","DOI":"10.1016\/j.nantod.2024.102331","volume":"57","author":"Z Xin","year":"2024","unstructured":"Xin Z, et al. Emerging IL-12-based nanomedicine for cancer therapy. Nano Today. 2024;57:102331.","journal-title":"Nano Today"},{"issue":"1","key":"1371_CR45","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, et al. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7(1):10541.","journal-title":"Sci Rep"},{"issue":"8","key":"1371_CR46","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint Blockade resist tumor-mediated Inhibition. J Clin Investig. 2016;126(8):3130\u201344.","journal-title":"J Clin Investig"},{"issue":"21","key":"1371_CR47","doi-asserted-by":"publisher","first-page":"15674","DOI":"10.3390\/ijms242115674","volume":"24","author":"HN Abramson","year":"2023","unstructured":"Abramson HN. Immunotherapy of multiple myeloma: current status as prologue to the future. Int J Mol Sci. 2023;24(21):15674.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1371_CR48","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clml.2023.03.016","volume":"23","author":"M Bhutani","year":"2023","unstructured":"Bhutani M, et al. A clinical and correlative study of elotuzumab, carfilzomib, Lenalidomide, and dexamethasone (Elo-KRd) for Lenalidomide refractory multiple myeloma in first relapse. Clin Lymphoma Myeloma Leuk. 2023;23(7):535\u201344. e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"1371_CR49","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, et al. CD19 CAR\u2013T cells of defined CD4+: CD8\u2009+\u2009composition in adult B cell ALL patients. J Clin Investig. 2016;126(6):2123\u201338.","journal-title":"J Clin Investig"},{"issue":"4","key":"1371_CR50","doi-asserted-by":"publisher","first-page":"101097","DOI":"10.1016\/j.beha.2019.101097","volume":"32","author":"ML Cooper","year":"2019","unstructured":"Cooper ML, DiPersio JF. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies. Best Pract Res Clin Haematol. 2019;32(4):101097.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"1371_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","volume":"31","author":"K Cwynarski","year":"2025","unstructured":"Cwynarski K, et al. TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1\/2 trial. Nat Med. 2025;31(1):137\u201343.","journal-title":"Nat Med"},{"issue":"4","key":"1371_CR52","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","volume":"4","author":"G Ritchie","year":"2018","unstructured":"Ritchie G, et al. Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis. JAMA Oncol. 2018;4(4):522\u20138.","journal-title":"JAMA Oncol"},{"key":"1371_CR53","doi-asserted-by":"crossref","unstructured":"Pan J, et al. Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia. American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.6518"},{"key":"1371_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27546","author":"M Hallek","year":"2025","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. 2025. https:\/\/doi.org\/10.1002\/ajh.27546.","journal-title":"Am J Hematol"},{"issue":"5","key":"1371_CR55","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","volume":"32","author":"H Jetani","year":"2018","unstructured":"Jetani H, et al. CAR T-cells targeting FLT3 have potent activity against FLT3\u2009\u2013\u2009ITD\u2009+\u2009AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018;32(5):1168\u201379.","journal-title":"Leukemia"},{"key":"1371_CR56","doi-asserted-by":"crossref","unstructured":"Wolter T, Wang Y, Hu Q. Engineering strategies to mitigate toxicities associated with CAR-T cell therapy. BMEMat, 2024:e12109.","DOI":"10.1002\/bmm2.12109"},{"issue":"12","key":"1371_CR57","doi-asserted-by":"publisher","first-page":"e0166891","DOI":"10.1371\/journal.pone.0166891","volume":"11","author":"K Minagawa","year":"2016","unstructured":"Minagawa K, et al. In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia. PLoS ONE. 2016;11(12):e0166891.","journal-title":"PLoS ONE"},{"issue":"32","key":"1371_CR58","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","volume":"36","author":"JK Lin","year":"2018","unstructured":"Lin JK, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018;36(32):3192\u2013202.","journal-title":"J Clin Oncol"},{"key":"1371_CR59","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","volume":"9","author":"RS Mehta","year":"2018","unstructured":"Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol. 2018;9:283.","journal-title":"Front Immunol"},{"issue":"9","key":"1371_CR60","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/17474086.2017.1350575","volume":"10","author":"C Georgiadis","year":"2017","unstructured":"Georgiadis C, Qasim W. Emerging applications of gene edited T cells for the treatment of leukemia. Expert Rev Hematol. 2017;10(9):753\u20135.","journal-title":"Expert Rev Hematol"},{"key":"1371_CR61","doi-asserted-by":"crossref","unstructured":"Imanei-Avaz M, et al. Changes in the expression of DNMTs before and after treatment with methotrexate (MTX)\/Mercaptopurine (6-MP) in B-Cell ALL children. Iranian Journal of Pediatric Hematology & Oncology; 2024.","DOI":"10.18502\/ijpho.v14i2.15267"},{"issue":"3","key":"1371_CR62","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaoncol.2022.5959","volume":"9","author":"M Provencio","year":"2023","unstructured":"Provencio M, et al. Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non\u2013small cell lung cancer with high tumor mutation burden: a nonrandomized controlled trial. JAMA Oncol. 2023;9(3):344\u201353.","journal-title":"JAMA Oncol"},{"key":"1371_CR63","doi-asserted-by":"publisher","first-page":"565257","DOI":"10.3389\/fimmu.2020.565257","volume":"11","author":"J Pagel","year":"2020","unstructured":"Pagel J, et al. Increased regulatory T cells precede the development of bronchopulmonary dysplasia in preterm infants. Front Immunol. 2020;11:565257.","journal-title":"Front Immunol"},{"issue":"1","key":"1371_CR64","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-023-01783-1","volume":"22","author":"S Huang","year":"2023","unstructured":"Huang S, et al. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. Mol Cancer. 2023;22(1):80.","journal-title":"Mol Cancer"},{"issue":"2","key":"1371_CR65","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, et al. Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell. 2016;167(2):419\u201332. e16.","journal-title":"Cell"},{"key":"1371_CR66","doi-asserted-by":"crossref","unstructured":"Montoya M et al. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives. Cells.\u00a02024; 13:726","DOI":"10.3390\/cells13090726"},{"key":"1371_CR67","doi-asserted-by":"crossref","unstructured":"Nejati B, et al. Cancer-on-chip: a breakthrough organ-on-a-chip technology in cancer cell modelling. Med Biol Eng Comput. 2025;63:321\u2013337.","DOI":"10.1007\/s11517-024-03199-5"},{"key":"1371_CR68","doi-asserted-by":"crossref","unstructured":"Hariri M, et al. Biosensor-based nanodiagnosis of carcinoembryonic antigen (CEA): an approach to classification and precision detection of cancer biomarker. Bionanosci. 2024;14:429\u2013446.","DOI":"10.1007\/s12668-023-01250-7"},{"issue":"10","key":"1371_CR69","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/CM9.0000000000003111","volume":"137","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Dawn of CAR-T cell therapy in autoimmune diseases. Chin Med J. 2024;137(10):1140\u201350.","journal-title":"Chin Med J"},{"key":"1371_CR70","doi-asserted-by":"crossref","unstructured":"Nadeem O, et al. Long-Term Follow-Up defines the population that benefits from early interception in a High-Risk smoldering multiple myeloma clinical trial using the combination of Ixazomib, Lenalidomide, and dexamethasone. medRxiv; 2024.","DOI":"10.1101\/2024.04.19.24306082"},{"key":"1371_CR71","doi-asserted-by":"publisher","first-page":"107186","DOI":"10.1016\/j.phrs.2024.107186","volume":"203","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, et al. Mesothelin CAR-T cells expressing tumor-targeted Immunocytokine IL-12 yield durable efficacy and fewer side effects. Pharmacol Res. 2024;203:107186.","journal-title":"Pharmacol Res"},{"issue":"10","key":"1371_CR72","doi-asserted-by":"publisher","first-page":"2200130","DOI":"10.1002\/adtp.202200130","volume":"5","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, et al. A computational model of cytokine release syndrome during CAR T-Cell therapy. Adv Ther. 2022;5(10):2200130.","journal-title":"Adv Ther"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01371-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01371-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01371-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:02:12Z","timestamp":1779519732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01371-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01371-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work, the author(s) used ChatGPT in order to enhance the clarity, grammar, and flow of the writing. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI and AI-assisted Technologies in the Writing Process"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}}],"article-number":"28"}}